Indian Pharmaceutical Supplier to the UK.
M Care has been an Indian pharmaceutical supplier to UK hospital pharmacy, specialist-importer and NHS framework buyers since our earliest export years. Mumbai runs the account; our London commercial desk sits close to Heathrow's pharma airside corridor and walks in and out of Trust procurement meetings in person. If you are a Chief Pharmacist, procurement pharmacist, category lead or homecare manager looking for an MHRA-approved supplier from India with genuine WHO-GMP manufacturing behind it, this page is the short version of how we work.
The British regulatory map, as we navigate it.
The Medicines and Healthcare products Regulatory Agency (MHRA) is the single gatekeeper for human medicines on the UK market. Post-Brexit, Great Britain and Northern Ireland are two zones: GB sits under MHRA alone, NI still follows EU rules under the Windsor Framework. We run the GB track as our default and add the NI variation when a delivery address requires it.
Routine wholesale movement sits under the Wholesale Dealer's Authorisation for Human medicines, WDA(H). Our associated London warehouse holds a current WDA(H), which is what lets us accept, quarantine, release and dispatch stock into UK trusts and pharmacies. For unlicensed product supplied against a specific patient's clinical need, we work under Regulation 167 of the Human Medicines Regulations 2012, commonly called the named-patient route, and alongside the MHRA Specials regime for UK-manufactured unlicensed specials. Named-patient import UK paperwork, signed prescriber declaration, MHRA notification where required, and full batch traceability are assembled by our London desk before any shipment leaves Mumbai.
Controlled drugs are a distinct workstream. Schedule 2 and Schedule 3 molecules move only through our Home Office controlled-drug-licensed partner; we do not touch them outside that route. Expect 3 to 6 weeks on a first CD line, 5 to 10 working days on repeats. Labelling for the UK is English, MHRA-compliant PIL and carton, with FMD-equivalent serialisation where the line is within scope.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · info@mcareexports.com · Mon–Sat 09:30–18:30 IST
Six capabilities, assembled and ready.
MHRA Specials supply
Bespoke-formulation and small-batch manufacture through MHRA-licensed Specials partners, typically 5 to 15 working days depending on dosage form. We quote pack-size, excipient profile and stability data up front, so your ward pharmacist is not chasing a CofA three days before dispense.
Named-patient imports (Reg 167)
Same-day acknowledgement and 48-hour firm quotation on named-patient import UK enquiries from the London desk. Prescriber declaration, clinical justification and MHRA notification where required are handled by our regulatory team, not pushed back to the hospital pharmacy.
NHS Supply Chain & CMU tenders
Full-stack NHS framework generic supply responses: Commercial Medicines Unit bids, NHS Supply Chain pricing submissions and Trust-level RFQs, with stability data, continuity-of-supply narrative and SKU-level pack configuration. We will not bid on a line we cannot back with 6 months of covered stock.
Hospital pharmacy supply
Routine and emergency supply into UK hospital pharmacy: cold-chain biologicals, oncology, controlled-drug cabinet stock, theatre consumables and unlicensed imports. Single purchase-order portal, batch-level traceability, audit-ready documentation for CQC and GPhC inspections.
WDA(H) bonded stock at LHR
Consignment stock at our partner's HMRC-approved bonded warehouse near Heathrow, held under WDA(H) and drawn down against weekly call-off. For customers on a rolling 6-month forecast this removes 7 to 10 days from the order-to-shelf clock and shifts working inventory off the Trust balance sheet.
Homecare & dispensing-appliance
Supply into UK homecare operators on recurring patient scripts, including CIVAS-ready aseptic presentations and fridge-line biosimilars. Forecast-driven dispatch into the homecare provider's hub, with cold-chain data-logger files attached to every delivery note.
How stock actually moves from Mumbai to a UK ward.
Ninety percent of our UK volume flies. The default pharma lane is CSM Mumbai (BOM) to Heathrow (LHR), direct, 9 to 10 hours in the air. Our dispatch cut-off at BOM is 14:00 IST for a same-day wheels-up on the overnight freighter block; clearance at LHR Horseshoe sheds, airside pharma handling and bonded-warehouse put-away typically close the door-to-door window at 3 to 5 days for a standard pharma-air booking. For overnight reposition into the Midlands and the North we use East Midlands (EMA) as a secondary pharma cargo hub.
Cold-chain lanes run on Envirotainer RKN e1 and the RAP series for 2–8 °C bulk; for smaller consignments we use Pelican BioThermal Credo Cube and the Sofrigam TPi passive range. Temperature is logged continuously on Sensitech TempTale or Xsense Elite loggers with data files attached to the airway bill and forwarded to the receiving hospital pharmacy within an hour of touchdown at LHR. For frozen biologicals we hold −25 °C and −70 °C capability on selected lanes, validated for 96-hour hold.
Ambient, non-urgent palletised supply moves by sea via Felixstowe or Tilbury, 22 to 28 days door-to-door, priced for tenders where landed cost matters more than next-week availability. Commercial terms on a first engagement are typically 100% telegraphic transfer against pre-shipment documents; from order two onwards most UK customers migrate to LC at sight or open account 30 days, with 60 and 90-day terms opening up once the relationship and volumes settle. We do not ask a first-time UK buyer to commit to a year-long contract to get a sample batch moving.
Where our UK volume actually sits.
The British hospital formulary is not the same shopping list as the Gulf or West Africa, and we do not pretend otherwise. Our UK volume is weighted towards four therapy areas where demography, NHS tender patterns and the strength of our Indian manufacturing base align.
Oncology is the largest slice, both injectable and oral. Cytotoxic staples, supportive-care lines (anti-emetics, G-CSFs, bisphosphonates) and a growing biosimilar book go into UK chemotherapy day units and specialist cancer centres under NHS framework generic supply. Anti-infectives are the second volume bucket: carbapenems, glycopeptides, antifungals and a broad oral antibiotic shelf, driven by antimicrobial-stewardship formularies and the recurring supply-disruption cycle on several molecules where Indian manufacturing is now the global back-up source.
Cardiovascular and diabetes lines are the steady ambient-stock backbone, everything from beta-blockers and ACE inhibitors through DOACs to insulin analogue biosimilars. Finally, CNS and named-patient imports (unlicensed paediatric formulations, rare-disease specials, compassionate-use compounds) round out the portfolio and are the quickest route for a new UK hospital pharmacy customer to try us out before scaling onto a framework line.
A regional NHS acute Trust came to us in Q2 2024 facing a 16-week manufacturer shortage on a first-line chemotherapy agent. The London desk identified a WHO-GMP equivalent from one of our Gujarat-based partners, assembled MHRA-acceptable documentation including stability data and batch release paperwork, and had validated stock on the hospital pharmacy shelf within 11 working days of the initial call. The Trust carried forward a standing supply agreement on that molecule, and has since added two further oncology lines and a cold-chain biosimilar to the account. Stockout incidents across the three lines in the first twelve months: zero.
Why Indian pharma, and why M Care specifically.
The structural case for sourcing from India is familiar to any UK procurement pharmacist who has watched the last five years of supply-chain turbulence: a manufacturing base that carries 20%+ of global generic volume, a cost structure that still undercuts most European-manufactured equivalents on comparable quality, and WHO-GMP sites that are in most cases also inspected by MHRA, EMA or the US FDA. The question has moved from "is Indian product acceptable" to "which Indian supplier can actually deliver to UK hospital pharmacy standards, in the time I have." UK hospital pharmacy Indian pharmaceutical supply is not a novelty anymore; it is a live category on most NHS framework lines.
What M Care brings is the Mumbai HQ plus the London commercial desk, in one account structure. You get a single named account manager on a single line (+91 70156 05768, direct to the Mumbai desk), with in-market support at the London office when you need a face in the room. Our dossiers are CTD/eCTD-ready out of Mumbai, our manufacturing partners are WHO-GMP as a floor and EU-GMP / MHRA-inspected where the molecule requires it, and our cold-chain track record runs on validated BOM–LHR lanes with continuous temperature logging. We do not quote prices we cannot hold for 90 days, we do not bid on tender lines we cannot back with stock, and we will tell you at the enquiry stage if we are not the right counterparty for a given line rather than walk you into a supply gap.
What British buyers usually ask us first.
Do you supply under the MHRA Specials regime?
Yes. We work alongside MHRA-licensed Specials manufacturers in the UK and supply unlicensed medicines against named clinical need under Regulation 167 of the Human Medicines Regulations 2012. Typical acknowledgement on a Specials enquiry is the same working day, with a firm quotation inside 48 hours once the prescribing clinician's paperwork lands with our London desk.
Are your manufacturing partners MHRA-inspected?
Our Indian manufacturing partners operate under WHO-GMP and, for lines that require it, hold EU-GMP or MHRA-inspected status. We can provide the latest inspection report, Site Master File extract and batch Certificate of Analysis ahead of any trial order so that your Chief Pharmacist or QA lead can sign off on the supply chain before a purchase order is raised.
Do you import Schedule 2 or Schedule 3 controlled drugs into the UK?
Controlled-drug imports are handled through a partner who holds a current Home Office controlled-drug licence and the matching WDA(H). We do not move Schedule 2 and 3 molecules outside of that licensed route. Lead time on a first-time CD line is typically 3 to 6 weeks depending on Home Office clearance; repeat cycles run to a 5 to 10 working-day rhythm.
How do you respond to NHS framework tenders?
The London desk assembles NHS Supply Chain, Commercial Medicines Unit and Trust-level bids end-to-end: pricing, stability data, pack configuration, continuity-of-supply plan and all Section 5 commercial schedules. Most framework submissions are turned around in 5 to 7 working days from the RFT drop. We will not submit a line we cannot hold stock against.
What happens with Northern Ireland under the Windsor Framework?
Great Britain and Northern Ireland are now effectively two regulatory zones. GB product sits under MHRA alone; NI product must meet EU rules via the Windsor Framework, which in practice means a separate dossier variation and FMD-compliant serialisation on the pack. We run both tracks and will flag at the quote stage which route applies to your delivery address.
Which ports and airports do you use for UK supply?
The default pharma lane is BOM–LHR direct, with airside clearance at Heathrow and road-feeder into our associated bonded warehouse. East Midlands (EMA) is our secondary air hub for overnight repositioning into the Midlands and the North. For ambient, non-urgent palletised supply we route sea freight via Felixstowe or Tilbury, typically 22 to 28 days door-to-door.
Do you offer consignment or bonded stock in the UK?
Yes, for customers holding a rolling forecast of 6 months or more. Stock can sit bonded at our partner's HMRC-approved warehouse near Heathrow under the WDA(H), drawn down against weekly call-offs. This typically removes 7 to 10 days from a Trust's order-to-shelf clock and lets Chief Pharmacists hold working inventory off the hospital balance sheet.
Why buyers choose M Care for the India → the United Kingdom corridor.
MHRA fluency
Dossiers built to the exact format MHRA reviews, not a generic CTD dump. We know which modules get scrutinised first, which stability data triggers queries, and which legalisation and apostille chain the submission needs to clear on the first pass.
Logistics you can schedule around
BOM → LHR direct air for time-critical orders, and Felixstowe for high-volume ambient sea freight. Cold-chain SKUs run on validated containers with continuous temperature logging. Consolidation at origin so you order by molecule, not by MOQ.
Commercial discipline, one point of contact
USD invoicing with clear FX-clause language, LC / TT / open-account progression as the relationship proves out, 18 therapeutic areas on one PO, and one named account manager from enquiry through clearance in the UK.
Top categories we ship to the UK
Anti-infectives
Penicillins, cephalosporins, carbapenems, antivirals, antimalarials — 1,800+ hospital and retail lines.
Cardiovascular
Antihypertensives, statins, anticoagulants, antiarrhythmics and heart-failure lines.
UK Oncology supply →
NHS, MHRA specials, private oncology — bortezomib, docetaxel, paclitaxel, gemcitabine, oxaliplatin and 120+ SKUs.
Diabetes & endocrine
Insulins, oral antidiabetics, thyroid and hormonal therapy — 470+ lines across the spectrum.
CNS & neurology
Antiepileptics, antipsychotics, antidepressants, anxiolytics and neuroprotective lines.
General & OTC
Analgesics, vitamins, wound-care, nutritionals — 1,283 SKUs, our broadest catalogue.
Molecule, volume, ship-to. One working day to a quote.
Your enquiry goes directly to the account manager responsible for the United Kingdom desk. No call-centre hops, no generic autoresponders, just the answer a procurement pharmacist can actually act on.
Start a United Kingdom enquiry → Back to all markets